Analysis Group to Present New Research on Comparative Effectiveness and Health Outcomes at International Society for Pharmacoeconomics and Outcomes Research Annual Meeting
Expertise in Health Outcomes Research Displayed in Workshop Session and 27 Poster Presentations
Date:May 27, 2014
Boston -- Members of Analysis Group's Health Care practice will serve as discussion leaders of a workshop session and exhibit 27 posters at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting in Montreal, May 31 -- June 4, 2014. The firm's significant presence at ISPOR highlights its depth and breadth of experience in outcomes research and reinforces its position as a leader in this field.
The conference theme, "Examining the Role of Big Data in Health Care Decision Making," underscores the promise and challenges of large data sets and advanced analytics in research, evidence, and drug development for pharmaceutical, biotechnology, and medical device industries.
Managing Principal Eric Wu, Vice President James Signorovitch, and Manager Keith Betts will lead the workshop "Identifying High-Value Treatment Populations in Clinical Trials and Real-World Data" (June 3, Workshop Session II).
Analysis Group's Health Care consultants will present 27 posters focused on cost-of-illness and comparative effectiveness studies targeting hepatitis C, acute coronary syndrome, multiple sclerosis, sickle cell disease, HIV, hemophilia, schizophrenia, opioid abuse, and lung cancer, as well as health care resource utilization in the United States, Canada, and China. Among the posters to be presented:
- A study led by Dr. Wu and Vice President Jipan Xie that calculates the inpatient costs of venous thromboembolism (VTE) to be 1.7 times as high as the average household income in China (Poster PCV43). It is the first study to comprehensively examine the current management and economic burden of VTE in China using high-quality Electronic Medical Records data.
- Two studies focused on the costs of opioid abuse -- the first updates estimates of the economic burden of opioid abuse among commercially insured patients in the United States; the second considers the characteristics of high-cost patients diagnosed with opioid abuse. Both studies were conducted by research teams led by Principal Howard Birnbaum and including Managers Brad Rice and Noam Kirson (Poster PMH34; Poster PMH36).
- A study led by Managing Principal Mei Sheng Duh and Vice President Sander Yermakov that indirectly analyzes the prophylactic efficacy of treatments for hemophilia A based on the published results of current products and simulated effects of potential differences in real-world compliance (Poster PSY40).
- A study that examines the cost effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection, led by Vice President James Signorovitch and colleagues (Poster PIN54).
- A study that offers a comparative analysis of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting, with a research team including Dr. Duh and Vice President Patrick Lefebvre (Poster PMH33).
A presentation guide of Analysis Group's podium and poster presentations can be downloaded from the firm's website.
About Analysis Group
Analysis Group provides health outcomes research and economic consulting to leading corporations, organizations, and government agencies. The firm has more than 500 professionals, with offices nationally in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, and Washington, D.C.; and internationally in Beijing and Montreal.